204 related articles for article (PubMed ID: 38491381)
1. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
3. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
4. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
5. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
Lamers CH; Sleijfer S; van Steenbergen S; van Elzakker P; van Krimpen B; Groot C; Vulto A; den Bakker M; Oosterwijk E; Debets R; Gratama JW
Mol Ther; 2013 Apr; 21(4):904-12. PubMed ID: 23423337
[TBL] [Abstract][Full Text] [Related]
8. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.
Lamers CH; Klaver Y; Gratama JW; Sleijfer S; Debets R
Biochem Soc Trans; 2016 Jun; 44(3):951-9. PubMed ID: 27284065
[TBL] [Abstract][Full Text] [Related]
16. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
[TBL] [Abstract][Full Text] [Related]
18. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
19. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
[TBL] [Abstract][Full Text] [Related]
20. Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.
Rana S; Nissen F; Marr A; Markert A; Altmann A; Mier W; Debus J; Haberkorn U; Askoxylakis V
PLoS One; 2012; 7(5):e38279. PubMed ID: 22693612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
